Ratings Werewolf Therapeutics, Inc.

Equities

HOWL

US95075A1079

Real-time Estimate Cboe BZX Other stock markets 20:49:58 29/04/2024 BST			5-day change	1st Jan Change
6.73 ^USD	-0.30%		+9.77%	+73.19%

04-23	Werewolf Therapeutics, Inc. Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease at AAI Annual Meeting	CI
04-05	Werewolf Therapeutics, Inc. Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
WEREWOLF THERAPEUTICS, INC.	+73.19%	293M	C-
IQVIA HOLDINGS INC.	+1.53%	42.75B	B
LONZA GROUP AG	+47.70%	41.61B	A
MODERNA, INC.	+12.02%	41.34B	B-
CELLTRION, INC.	-8.83%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+6.90%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.06%	18.12B	B
MEDPACE HOLDINGS, INC.	+30.30%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.33%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+8.61%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes